Cargando…

Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study

BACKGROUND: The disease-modifying therapies (DMTs) largely used in multiple sclerosis (MS) may result in higher infectious risk. OBJECTIVE: We aimed to investigate the infectious risk in DMT-treated MS patients. METHODS: MS patients were evaluated for infectious risk before starting, switching or du...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zingaropoli, Maria Antonella, Pasculli, Patrizia, Iannetta, Marco, Perri, Valentina, Tartaglia, Matteo, Crisafulli, Sebastiano Giuseppe, Merluzzo, Chiara, Baione, Viola, Mazzochi, Lorenzo, Taglietti, Ambra, Pauri, Flavia, Frontoni, Marco, Altieri, Marta, Gaeta, Aurelia, Antonelli, Guido, Conte, Antonella, Mastroianni, Claudio Maria, Ciardi, Maria Rosa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733376/ https://www.ncbi.nlm.nih.gov/pubmed/35003758 http://dx.doi.org/10.1177/20552173211065731

Ejemplares similares

Evaluation of BAFF, APRIL and CD40L in Ocrelizumab-Treated pwMS and Infectious Risk
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)

Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine
por: Dominelli, Federica, et al.
Publicado: (2022)

JCPyV NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis
por: Ciardi, Maria Rosa, et al.
Publicado: (2020)

The peripheral blood immune cell profile in a teriflunomide-treated multiple sclerosis patient with COVID-19 pneumonia
por: Ciardi, Maria Rosa, et al.
Publicado: (2020)

Evaluation of the Psychometric Properties of Jebsen Taylor Hand Function Test (JTHFT) in Italian Individuals With Multiple Sclerosis
por: Berardi, Anna, et al.
Publicado: (2022)

Increased sCD163 and sCD14 Plasmatic Levels and Depletion of Peripheral Blood Pro-Inflammatory Monocytes, Myeloid and Plasmacytoid Dendritic Cells in Patients With Severe COVID-19 Pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2021)

Evaluation of the Psychometric Properties of the Health Assessment Questionnaire (HAQ) in a Population of Individuals With Multiple Sclerosis
por: Berardi, Anna, et al.
Publicado: (2022)

Early IgG / IgA response in hospitalized COVID-19 patients is associated with a less severe disease
por: Fedele, Giorgio, et al.
Publicado: (2022)

Dynamic changes of MMP-9 plasma levels correlate with JCV reactivation and immune activation in natalizumab-treated multiple sclerosis patients
por: Iannetta, Marco, et al.
Publicado: (2019)

Diagnostic Value of JC Polyomavirus Viruria, Viremia, Serostatus and microRNA Expression in Multiple Sclerosis Patients Undergoing Immunosuppressive Treatment
por: Prezioso, Carla, et al.
Publicado: (2022)

Major reduction of NKT cells in patients with severe COVID-19 pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2021)

Reactivation of Hepatitis B Virus With Immune-Escape Mutations After Ocrelizumab Treatment for Multiple Sclerosis
por: Ciardi, Maria R, et al.
Publicado: (2018)

Higher Levels of Osteoprotegerin and Immune Activation/Immunosenescence Markers Are Correlated with Concomitant Bone and Endovascular Damage in HIV-Suppressed Patients
por: D’Abramo, Alessandra, et al.
Publicado: (2016)

Neuro-Axonal Damage and Alteration of Blood–Brain Barrier Integrity in COVID-19 Patients
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2022)

JC Virus-DNA Detection Is Associated with CD8 Effector Accumulation in Peripheral Blood of Patients with Multiple Sclerosis under Natalizumab Treatment, Independently from JC Virus Serostatus
por: Zingaropoli, Maria A., et al.
Publicado: (2018)

Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes?
por: Belvisi, Daniele, et al.
Publicado: (2022)

Neurophysiological and clinical biomarkers of secondary progressive multiple sclerosis: A cross-sectional study
por: Tartaglia, Matteo, et al.
Publicado: (2023)

Immunogenicity and Efficacy of Vaccination in People Living with Human Immunodeficiency Virus
por: Tortellini, Eeva, et al.
Publicado: (2023)

Immune Activation, Immunosenescence, and Osteoprotegerin as Markers of Endothelial Dysfunction in Subclinical HIV-Associated Atherosclerosis
por: D'Abramo, Alessandra, et al.
Publicado: (2014)

Quality of T-Cell Response to SARS-CoV-2 mRNA Vaccine in ART-Treated PLWH
por: Tortellini, Eeva, et al.
Publicado: (2022)

Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment
por: Pietropaolo, Valeria, et al.
Publicado: (2015)

Evaluation of Immunogenicity to Three Doses of the SARS-CoV-2 BNT162b2 mRNA Vaccine in Lung Transplant Patients
por: Guardiani, Mariasilvia, et al.
Publicado: (2022)

Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection
por: Salciccia, Stefano, et al.
Publicado: (2021)

Natalizumab Affects T-Cell Phenotype in Multiple Sclerosis: Implications for JCV Reactivation
por: Iannetta, Marco, et al.
Publicado: (2016)

Biomarkers of Neurological Damage: From Acute Stage to Post-Acute Sequelae of COVID-19
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)

COVID-19 Affects Serum Brain-Derived Neurotrophic Factor and Neurofilament Light Chain in Aged Men: Implications for Morbidity and Mortality
por: Petrella, Carla, et al.
Publicado: (2023)

Real-life use of tocilizumab with or without corticosteroid in hospitalized patients with moderate-to-severe COVID-19 pneumonia: A retrospective cohort study
por: Russo, Gianluca, et al.
Publicado: (2021)

Blood Biomarkers from the Emergency Department Disclose Severe Omicron COVID-19-Associated Outcomes
por: Pennacchia, Fiorenza, et al.
Publicado: (2023)

Abnormal Temporal Coupling of Tactile Perception and Motor Action in Parkinson’s Disease
por: Conte, Antonella, et al.
Publicado: (2017)

Tissue Inhibitor of Matrix Metalloproteinases-1 (TIMP-1) and Pulmonary Involvement in COVID-19 Pneumonia
por: Zingaropoli, Maria Antonella, et al.
Publicado: (2023)

The effect of stimulation frequency on transcranial evoked potentials
por: Leodori, Giorgio, et al.
Publicado: (2022)

Impact of IFN-Free and IFN-Based Treatment on Blood Myeloid Dendritic Cell, Monocyte, Slan-DC, and Activated T Lymphocyte Dynamics during HCV Infection
por: Vita, Serena, et al.
Publicado: (2020)

Botulinum Toxin Effects on Sensorimotor Integration in Focal Dystonias
por: De Bartolo, Maria Ilenia, et al.
Publicado: (2020)

Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis
por: Francone, Marco, et al.
Publicado: (2020)

Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy
por: Masci, Giorgio Maria, et al.
Publicado: (2021)

Early Atherosclerosis in HIV Infected Subjects on Suppressive Antiretroviral Treatment: Role of Osteoprotegerin
por: D'Abramo, Alessandra, et al.
Publicado: (2013)

B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications
por: Iannetta, Marco, et al.
Publicado: (2022)

Hepatitis B–Related Hepatic Flare During Immune Reconstitution Syndrome After Antiretroviral Treatment Initiation in an HBV Surface Antigen–Positive Patient With HIV: Viroimmunological and Histological Characterization
por: Iannetta, Marco, et al.
Publicado: (2022)

PaO(2)/FiO(2) ratio forecasts COVID-19 patients’ outcome regardless of age: a cross-sectional, monocentric study
por: Sinatti, Gaia, et al.
Publicado: (2021)

Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients
por: Marocco, Raffaella, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ef2br47mipumgbjseqmkmpac8d